GLP-1RAs show added protection against cancer beyond weight reduction

This post was originally published on News-medical.net

You will shortly be re-directed to the publisher's website

New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.